TY - JOUR
T1 - Interim 2024/25 influenza vaccine effectiveness
T2 - eight European studies, September 2024 to January 2025
AU - European IVE group
AU - Rose, Angela M.C.
AU - Lucaccioni, Héloïse
AU - Marsh, Kimberly
AU - Kirsebom, Freja
AU - Whitaker, Heather
AU - Emborg, Hanne Dorthe
AU - Botnen, Amanda Bolt
AU - O’Doherty, Mark G.
AU - Pozo, Francisco
AU - Hameed, Safraj Shahul
AU - Andrews, Nick
AU - Hamilton, Mark
AU - Trebbien, Ramona
AU - Møller, Karina Lauenborg
AU - Marques, Diogo F.P.
AU - Murphy, Siobhan
AU - McQueenie, Ross
AU - Lopez-Bernal, Jamie
AU - Cottrell, Simon
AU - Bucholc, Magda
AU - Kissling, Esther
AU - Parys, Anna
AU - Witdouck, Arne
AU - Delaere, Benedicte
AU - Lissoir, Benédicte
AU - Quoidbach, Catherine
AU - Sion, Catherine
AU - Brugerolles, Claire
AU - De Geyter, Deborah
AU - Lievens, Dylan
AU - Bernaert, Eva
AU - Van Honacker, Eveline
AU - Petit, Evelyn
AU - Genderini, Francesco
AU - Dufrasne, François
AU - Leroux-Roels, Isabel
AU - Flore, Katelijne
AU - Renard, Katty
AU - Magerman, Koen
AU - De Mot, Laurane
AU - Seyler, Lucie
AU - Bourgeois, Marc
AU - Bleyen, Marieke
AU - Parsy, Marie Pierre
AU - Reynders, Marijke
AU - Blommen, Marlies
AU - Nardone, Anthony
AU - Stowe, Julia
AU - Hoschler, Katja
AU - Zambon, Maria
N1 - Publisher Copyright:
© 2025 European Centre for Disease Prevention and Control (ECDC). All rights reserved.
PY - 2025/2/20
Y1 - 2025/2/20
N2 - The 2024/25 influenza season in Europe is currently characterised by co-circulation of influenza A(H1N1) pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness (VE) estimates from eight European studies (17 countries) indicate an all-age influenza A VE of 32–53% in primary care and 33–56% in hospital settings, with some signals of lower VE by subtype and higher VE against influenza B (≥ 58% across settings). Where feasible, influenza vaccination should be encouraged and other prevention measures strengthened.
AB - The 2024/25 influenza season in Europe is currently characterised by co-circulation of influenza A(H1N1) pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness (VE) estimates from eight European studies (17 countries) indicate an all-age influenza A VE of 32–53% in primary care and 33–56% in hospital settings, with some signals of lower VE by subtype and higher VE against influenza B (≥ 58% across settings). Where feasible, influenza vaccination should be encouraged and other prevention measures strengthened.
UR - http://www.scopus.com/inward/record.url?scp=85218993676&partnerID=8YFLogxK
U2 - 10.2807/1560-7917.ES.2025.30.7.2500102
DO - 10.2807/1560-7917.ES.2025.30.7.2500102
M3 - Article
AN - SCOPUS:85218993676
SN - 1025-496X
VL - 30
SP - 9
EP - 19
JO - Eurosurveillance
JF - Eurosurveillance
IS - 7
ER -
